Quietly replacing the old way: customers are switching to the company from an entrenched alternative, and the switching
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes customers switching from an entrenched alternative to their product, and that this switching is still early with most potential switchers not yet converted. The transcript discusses ProSense, a cryoablation system. Management talks about adoption, independent studies, regulatory approvals, and commercial expansion. They mention that ProSense is an alternative to surgery (lumpectomy) for breast cancer. They say "migrating to a minimally invasive solution like ours will improve the life of women by providing them with an alternative to lumpectomy." That suggests a substitution from surgery to cryoablation. But is it described as currently happening? They mention increased sales, new distributors, procedures performed. They say "ProSense is gaining significant traction and momentum amongst doctors, and we believe this translates into more system and disposable demand globally." They also mention "the first ever breast cancer cryoablation procedure in the country was performed using ProSense" in India. That's an early adoption. They talk about independent studies and conferences. They don't explicitly say that customers are switching from an entrenched alternative in large numbers, but they imply that surgery is the standard of care and they are offering an alternative. They also mention that the FDA denied De Novo for breast cancer, but they still have approvals elsewhere. The question is whether they describe a substitution underway with most potential switchers not yet converted. They say "we believe this translates into more system and disposable demand" - that's a belief, not a description of current switching. They also say "we are also experiencing a high-tended level of interest" - interest, not actual switching. They mention increased sales of 11% in systems and probes, but that's growth, not necessarily switching from an incumbent. The incumbent is surgery, not a specific product. They are offering a minimally invasive alternative. They don't quantify how many patients have switched vs. how many still use surgery. They don't say "we are displacing lumpectomy" in a present-tense way. They say "migrating to a minimally invasive solution like ours" - that's a future or ongoing trend, but not clearly described as already happening on a large scale.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| BIG | Big Lots, Inc. | Q1 2022 | 2022-05-27 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
BLKB · Q1 2017 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES Management describes customers switching from entrenched alternatives (legacy hardware systems, older Raiser's Edge versions, standalone point solutions) to Blackbaud's cloud solutions like NXT, with examples of recent replacements and migrations already occurring. They also note that much of the potential remains, as the installed base of legacy methods is still large 25% of subscription revenue, and they describe the opportunity as "really early days" with substantial distance left to run. This fits the criteria of a present-tense substitution pattern in the market, not just future hope. The high retention on their own base (93%) combined with declining maintenance revenue shows the shift is active and ongoing, while new wins against competitors and legacy alternatives are happening now. The TAM of $7 billion with hundreds of thousands of addressable customers reinforces that switching is early-stage relative to the total opportunity. The answer is YES. The question is answered with YES. The question is answered with YES.
BLZE · Q3 2022 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing current customer switches from entrenched alternatives (AWS for urlscan.io; Synology NAS/on-prem for Fiture; broader AWS and on-prem users), with these as real, ongoing patterns. They explicitly note that much of the potential remains ("so much of the world's data is still on-premises" and "customers that are inside of AWS and others"), confirming the substitution is early-stage relative to the large installed base. This is conveyed directly in Gleb's responses as a present-tense reality, not merely anticipated. The two examples plus the broader opportunity framing establish a coherent substitution underway, with the company being substituted in. The investor question on percentages and Gleb's reply reinforce the pattern without contradicting the current movement. No single-event or future-only framing applies here. Thus, both conditions are met.
APPS · Q1 2024 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing customers shifting from Apple/Google app stores to DT Hub and SingleTap-enabled alternative distribution as an ongoing, early-stage substitution. Bill Stone notes the company has already launched DT Hub with four U.S. operators and is generating revenue today, while highlighting "increasing pressure on the duopoly" and 5 monetization ways for SingleTap that enable publishers to direct-download apps outside traditional stores. He explicitly calls it "very early days and not yet material to our overall results" and "early innings," confirming the installed base of the old way remains large and the switch is just beginning with incremental RPD gains from devices engaging the new platform. This meets the criteria of a present-tense substitution underway, with the company positioned as the alternative being adopted.